- Home
- APRE vs PCLA Comparison
APRE vs PCLA Comparison
Compare APRE & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | PCLA |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | Japan |
| Employees | N/A | 55 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Building Products |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 9.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | APRE | PCLA |
|---|---|---|
| Price | $0.72 | $2.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | ★ 216.2K | 8.5K |
| Earning Date | 05-13-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.12 |
| 52 Week High | $2.22 | $8.00 |
Technical Indicators
Market Signals| Indicator | APRE | PCLA |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 41.18 |
| Support Level | $0.55 | $0.34 |
| Resistance Level | $0.98 | $3.74 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 48.08 | 63.62 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About PCLA PicoCELA Inc. American Depositary Shares
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.